Agilent, SISCAPA Sign Protein Quantitation Agreement
News May 27, 2014
This solution will combine SISCAPA Assay Technologies' (SAT) reagents for targeted protein quantitation with Agilent's Bravo Automated Liquid Handling Platform for sample preparation, along with liquid chromatography-mass spectrometers (LC/MS) for quantitative analysis. The agreement expands on an established strategic relationship between Agilent and SAT, furthering both companies' ability to enhance customer workflows.
SAT will provide an integrated solution for targeted protein measurement. A protocol for addition-only trypsin digestion followed by anti-peptide immunocapture enrichment has been developed for the Bravo platform and is complemented by a purpose-designed, intuitive software interface. The process supports preparation of 400 multiplexed samples per working day, with sensitive and selective mass analysis carried out using Agilent's triple quadrupole mass spectrometry instruments.
SISCAPA assays alleviate challenges of limited specificity and protein interferences seen with ligand binding assays and anti-protein immunocapture mass spectrometry. Subjecting the sample to up-front tryptic digestion and enriching for proteotypic peptides means SISCAPA assays measure the amount of a protein target in a highly multiplexed and high-throughput manner, free of such interferences. This greatly decreases the bottleneck of screening candidate protein biomarkers in clinical research.
"Agilent is a leader in workflow solutions, including high-precision sample preparation systems and rugged, sensitive LC/MS systems, and this partnership offers customers a truly enabling workflow to execute targeted protein assays with a throughput and precision that were previously impossible," said Yvonne Linney, vice president and general manager for Agilent's Life Science Solutions Division, which includes Automation and LC/MS businesses. "Agilent is pleased to partner with SISCAPA Assay Technologies, the leader in targeted protein quantitation, to offer researchers an integrated solution with simplified user interface, high-precision, sensitive quantitation and enhanced productivity."
SAT will offer complete systems comprised of its SISCAPA assay reagents combined with the Bravo platform and software and a broad offering of Agilent liquid chromatography and LC/MS systems including, but not limited to, Agilent's popular Triple Quadrupole LC/MS systems and RapidFire high throughput LC/MS system.
"This agreement enables our customers to combine the selectivity of anti-peptide immunocapture and MRM mass spectrometry to carry out quantitative protein measurement with high precision and minimal user intervention," said Selena Larkin, vice president of Marketing and Sales at SAT. "As part of this complete solution, SAT will offer all the components required to implement the workflow as well as provide technical support for assay execution. The seamless end-to-end solution is now available from SISCAPA Assay Technologies."
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE